Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawmakers Question FDA On Medical Device Cybersecurity Concerns

Executive Summary

Top lawmakers on the House Energy and Commerce Committee wrote to US FDA asking what the agency is doing to ensure devices are protected against malicious hackers.

You may also be interested in...



Feds Holding Workshop on Medical Device Cybersecurity Gaps

Following several cases highlighting medical device cybersecurity vulnerabilities and concerns from experts and lawmakers about the federal government's response, FDA is joining with Homeland Security and the National Science Foundation to hold a two-day workshop to discuss potential gaps and how to fix them.

Medtech Cybersecurity Whistleblowers: Traditional Protections, Incentives Apply

As the medical device industry enters a brave new world of connected products, cybersecurity vulnerabilities and hacking threats have surfaced, raising many questions. Among them: what protections are available to employees who raise the alarm about cybersecurity problems with a device sold by their company. Attorney Alexis Ronickher addresses this question in this article and in a Medtech Insight podcast interview.

FDA Recommends Security Patch For St. Jude Wireless Cardiac Devices

Following months of bickering between St. Jude and Muddy Waters Research, US FDA issued a safety alert for the device-maker's wireless cardiac devices. The agency says there's a risk for malicious cyber-attacks and recommends a software patch to minimize risk.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel